

Antibiotic Susceptibility Testing, Plasmid Detection and Curing of Clinically Isolated *Enterococcus* Species

G. A. C. Ezeah^{1*}, M. C. Ugwu², A. O. Ekundayo³, O. F. Odo⁴, O. C. Ike⁵
and R. A. Akpe³

¹Department of Microbiology, Enugu State University Teaching Hospital Parklane, Enugu State, Nigeria.

²Department of Medical Laboratory Science, College of Health Sciences, Nnamdi Azikiwe University, PMB 5001Nnewi, Anambra State, Nigeria.

³Department of Microbiology, Ambrose Alli University, Ekpoma, Edo State, Nigeria.

⁴Department of Histopathology, Enugu State University Teaching Hospital Parklane, Enugu State, Nigeria.

⁵Department of Industrial Chemistry, Enugu State University of Science and Technology, Enugu State, Nigeria.

Original Research Article

ABSTRACT

Vancomycin resistant enterococci (VRE) are a major medical concern globally. Their significantly greater prevalence and the ability to transfer resistance to vancomycin from other bacteria made them an object of interest and intense research. The isolates of *Enterococcus* sp. were subjected to antibiotic susceptibility testing before curing. The three *Enterococcus* species exhibited different antibiotic resistance profile. Pre-curing antibiotic resistance of nosocomial isolates compared with community acquired isolates revealed that high percentage of the nosocomial isolates were resistant to antibiotics compared to community isolate. Post-curing antibiograms of the isolates showed different resistant and susceptibility pattern. Also, DNA plasmid pre-curing and post curing analysis of the isolates showed different resistance pattern. Six of the 15 representative isolates selected on the basis of their high pre-curing antibiotic resistance for plasmid analysis with 0.8% agarose electrophoresis were positive for plasmid DNA. Four (4) of the positive isolates (*E. faecium*, *E. faecium*, *E. faecalis*, and *E. avium*) had plasmid fragment of greater than 1000 bp while two (2) of them (*E. faecalis* and *E. faecalis*) had fragments of between 100 and 500 bp. The remaining nine (9) had no plasmid DNA. The study revealed the pathogenicity factors demonstrated with the enterococcal isolates.

Keywords: *Enterococci*, antibiotic susceptibility, DNA, plasmid detection, pathogenicity.

1. INTRODUCTION

High level of intrinsic antibiotic resistance is one of the important features of the genus

Enterococcus. Some of them are intrinsically resistant to some β -lactam-based antibiotics (some penicillins and virtually all cephalosporins) as well as to many aminoglycosides [1]. Between

*Corresponding author: E-mail: ezeahg@yahoo.com, princeconsult@yahoo.com;

1989 and 2009, strains of particularly virulent and vancomycin-resistant enterococci (vancomycin-resistant Enterococcus or ERV) emerged in hospital-acquired nosocomial infections, particularly in the United States of America [2].

Resistance to vancomycin occurs when a sensitive enterococcus acquires a plasmid that confers resistance to vancomycin. The new strain is called vancomycin resistant *Enterococcus* (VRE). Unrelated bacteria such as methicillin resistant *Staphylococcus aureus* (MRSA) can acquire vancomycin resistance from VRE to form new strains called VRSA. Furthermore, MRSA (VRE organisms) are usually resistant to more than one antibiotic [2]. VRE can be transmitted from person to person and are increasing problems in chronic hospitalized patients. The most prevalent *enterococcus* species in humans are *Enterococcus faecalis* and *Enterococcus faecium*; contributing to more than 90% of clinical isolates [3]. Other enterococcal species are: *Enterococcus avium*, *Enterococcus gallinarum*, *Enterococcus casseliflavus*, *Enterococcus durans*, *Enterococcus raffinosus* and *Enterococcus mundtii*. The most vancomycin resistant strain is *E. faecium* [2].

Enterococci's acquisition of vancomycin resistance has seriously affected these organisms' treatment and infection control. Six phenotypes of vancomycin resistance termed vanA, vanB, vanC, vanD, vanE and vanG have been described. The vanA, vanB phenotypes are clinically significant and mediated by 1-2 acquired transferable operons that consist of 7 genes in 2 clusters termed VANA VANB operons. First reported in enterococcal strains were these gene clusters in 1988. VanA is carried on a plasmid-mediated Transposon Tn 1546 [4].

However, DNA plasmid curing achieved by treatments with some reagents is most likely to promote the loss of resident plasmid DNA from a cell and to cause loss of resistance. Curing of plasmid is done to determine whether a plasmid encodes a trait or not. A trait is said to be plasmid-borne if plasmid encodes information about it. Curing of plasmid could be achieved using any of these: novobiocin, ethidium bromide (EtBr), acriflavin, acridine orange dye, plumbagin, sodium deodecyl sulphate (SDS) [5].

Enterococci virulence is lower than organisms such as *Staph. aureus* [6]. Risk factors for mortality associated with enterococcal bacteraemia include disease severity, the age of

the patient and the use of broad-spectrum antibiotics [7]. Some enterococcal strains produce gelatinase, a proteolytic enzyme with an extracellular zinc containing metalloproteinase [8]. Gelatinase can hydrolyse gelatin, collagen, fibrinogen, casein, haemoglobin and other bioactive peptides [9]. It is also responsible in oral infection for inflamed pulp and periapical lesions [8]. Gelatinase has played a major role in most pathogenic bacteria's pathogenicity. Due to its cytotoxic and tissue destructive potential and inhibitory effects on phagocytes, the enzyme was associated with disease progression. [10]. The production and activity of gelatinase in enterococcal infections in clinical isolates are higher than that of healthy volunteers [11].

1.1 Vancomycin - Dependent *Enterococcus* (VDE)

In 1993, the first documented strain of vancomycin-dependent enterococcus (VDE) was isolated from the urine of a 46-year-old woman at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania [12]. Twenty additional cases of VDE have been reported worldwide since this first isolate was reported, including both *E. Faecalis* and *E. faecium* strains. Even though the clinical significance of VDE remains unclear, a 1999 outbreak of VDE was reported in a bone marrow transplant unit at Johns Hopkins University [13] and shows its potential to become a pathogen of clinical significance.

Another mechanism of enterococci resistance to antibiotics is the formation of biofilm. Biofilm is a population of cells in a hydrated matrix of exopolymeric substances, proteins, polysaccharides and nucleic acids that are irreversibly attached to many biotic and abiotic surfaces [14]. Biofilm formation is a complex development process involving surface attachment and immobilization, cell-to-cell interaction, microcolony formation, confluent biofilm formation and the development of a three-dimensional biofilm structure [15]. In a biofilm, bacteria behave differently from their free-floating counterparts (planktonic). By producing extracellular signal molecules called autoinducers, the regulation of bacterial gene expression in response to cell population density, called quorum sensing, is accomplished [16]. Biofilm production is regulated in several bacterial pathogens by quorum sensing systems. Biofilms are known to be hard to eradicate and are a source of many chronic infections. Biofilms are medically important, according to the

National Institutes of Health, accounting for more than 60% of microbial infections in the body [17]. A mature biofilm can tolerate antibiotics at concentrations of 10–1000 times more than are required to kill planktonic bacteria. Bacteria in biofilms are phagocytosis resistant, making it extremely difficult for biofilms to be eradicated from live hosts [17]. Bacteria in biofilms colonize a wide variety of medical devices, such as catheters, artificial cardiac pacemakers, heart valves and orthopedic devices, and are associated with a number of human diseases, including endocarditis of the valve, burning wound infections, chronic otitis media with effusion and cystic fibrosis [18].

2. MATERIALS AND METHODS

2.1 Study Area

Samples for this study were sourced from:

Enugu State University of Technology (ESUT) Teaching Hospital, Parklane and University of Nigeria Teaching Hospital (UNTH), Ituku/Ozalla in Enugu State, Nigeria.

Study design: This is a cross-sectional study. Three categories of patients were included in the study.

In-patients: 504 in-patients admitted in ESUT Teaching Hospital and University of Nigeria Teaching Hospital both in Enugu who submitted their samples of urine, wound swabs, aspirates, sputum, ear swabs, high vaginal swabs, urethral swabs, semen, CSF and blood to the Microbiology Departments for microscopy, culture and sensitivity.

Out-patients: 504 out-patients who visited ESUT Teaching Hospital, Parklane and University of Nigeria Teaching Hospital, Ituku/Ozalla and who submitted clinical samples to the Microbiology Departments for microscopy, culture and sensitivity.

Controls: 20 male and 20 female volunteers who did not have symptoms of any infection. They were selected from outside the hospital environment and were used as controls.

Sample collection: Sterile universal containers containing boric acid preservative were used for urine sample collection while sputum, stool, aspirates and CSF were collected with sterile

plain universal bottles. Sterile swabs were used to collect high vaginal, urethral, wound, nasal, ear, anal sample. For blood culture, five milliliters of blood was collected with syringe and put aseptically into fifty milliliters of sterile brain heart infusion (BHI) broth contained in a bijou bottle.

2.2 Vancomycin Susceptibility Testing

The vancomycin antibiotic susceptibility patterns of isolates were determined using disk diffusion method as described by CLSI [19]. Reference type *E. faecalis* strain (ATCC 29212) was used as control.

2.3 Other Antibiotic Susceptibility Patterns of Isolates

The isolates were subjected to antibiotic screening by disk diffusion method as described by CLSI [19]. Reference type *E. faecalis* strain (ATCC 29212) was used as control. The antibiotics used, their classes and disc concentrations were as follows:

- **Fluoroquinolones:** ciprofloxacin (5µg), pefloxacin (5µg), levofloxacin (5µg) and ofloxacin (5µg)
- **Cephalosporins (cephems):** cefuroxime (30µg) and ceftriaxone (30µg)
- **β- lactam -β- lactamase inhibitor combination:** augmentin (20/10µg)
- **Penicillins (β- lactams):** ampicillin (10µg) and cloxacillin (5µg)
- **Macrolides:** erythromycin (15µg)
- **Glycopeptides:** vancomycin (5µg)
- **Aminoglycosides:** gentamicin (10µg)

The interpretative criteria were based on CLSI [19].

2.4 Determination of Multiple Antibiotic Resistance (MAR) Index

The MAR index was determined by dividing the number of antibiotics to which the test isolate was resistant by the total number of antibiotics to which test isolate was evaluated for sensitivity using the formula $MAR = X/Y$, where X is the number of antibiotics to which test isolates displayed resistance and Y is the total number of antibiotics to which test organism was evaluated for sensitivity.

2.5 Plasmid Profile Analysis of Isolates Using 0.8% Agarose Gel Electrophoresis

The plasmid profile analysis of isolates using 0.8% agarose gel electrophoresis was carried out following the method described by Diana-Roxana *et al.* [20]. Fifteen isolates that were highly resistant to antibiotics were selected for plasmid analysis. These were six isolates of *E. faecium*; five isolates *E. faecalis* and four isolates of *E. avium*. The isolates were subjected to bacterial cultures for plasmid profile analysis.

2.6 Curing of Plasmid DNA

The curing (elimination) of the resistant plasmids of the enterococci isolated was done using sub-inhibitory concentration of 0.10 mg/ml of acridine

orange as described by Akortha and Filgona [21]. Isolates were grown for 24 hours at 37°C in Mueller-Hinton broth containing 0.1mg/ml acridine orange. The broth was agitated to homogenize the content and a loopful of the broth medium was cultured on Muller-Hinton agar (MHA) plates and antibiotic sensitivity testing was carried out as previously described. The resistant isolate that became sensitive after curing was regarded as having been cured of the plasmid DNA (plasmid-borne) while the isolate that remained resistant was not cured (chromosomal-borne).




Plate 1. Antibiotic susceptibility patterns of *Enterococcus* sp isolated during this study

2.7 The Pathogenicity Factors of the Isolates

These were determined by monitoring virulent determinants such as;

Haemolysin: Haemolysin production by the enterococcal isolates was assessed by a method described by Giridhara *et al.* [22].

Gelatinase: Gelatinase production by the enterococcal isolates was assessed by the liquefaction of yeast extract agar containing gelatine plates as described by Giridhara *et al.* [22].

Caseinase production: Casein hydrolysis was assessed as described by Archimbaud *et al.* [23].

Lipase production: Lipase activity was determined as described by Gunn *et al.* [24].

MSCRAMM-Ace: A drop of distilled water was placed on an end of a slide. A colony of the test organism was emulsified in the drop. A loopful of the patient's serum was added to the suspension and mixed gently. Clumping within 30 seconds indicated a positive reaction [22].

2.8 Detection of β -Lactamase Production

Using sterile forceps, a nitrocef disc (Oxoid Ltd) was removed from the vial and placed on an empty petri dish. Immediately the remaining unused disks were placed into the freezer. Prior to inoculation, the nitrocef disc was allowed to equilibrate to room temperature. Each disc was moistened with one drop of sterile deionized water. The disc was not allowed to over-saturate, which could dilute the reagent. Water is critical to the development of the color reaction, if the disc begins to dry out it may be necessary to

rehydrate the reaction area of the nitrocef disc with a small amount of water. With a sterilized loop, a well-isolated colony was removed and spread on the disc surface. The inoculated disc was observed for the development of an orange/red color.

A positive beta-lactamase result was recorded when the nitrocef disc changes color from its original yellow to orange or red. Most positive bacterial strains will produce a color change within 5-60 minutes. A positive beta-lactamase result predicts the following: Resistance to penicillin, ampicillin and amoxicillin as well as acylamino-, carboxy-, and ureido-penicillins. A negative beta-lactamase result was recorded when the Nitrocef Disc remains yellow in color. A negative result did not rule out resistance due to other mechanisms.

2.9 Statistical Analysis of Results

The results obtained from this work were analyzed statistically using Chi-square with computer program SPSS version 18 to show significant different.

3. RESULTS

3.1 Susceptibility Testing, Plasmid Detection and Curing

3.1.1 Summary of precuring antibiogram of the isolates

The 68 isolates of *Enterococcus* sp. were subjected to antibiotic susceptibility testing before curing using twelve (12) commonly used antibiotics in the study area as shown in Table 1.

68 (100%) of the isolates were resistant to the penicillins (β -lactams) in this work which were ampicillin and cloxacillin. The isolates exhibited high level of sensitivity to β -lactam- β -lactamase inhibitor which was represented by augmentin, 10 (14.7%) of the isolates were resistant to augmentin while 58 (85.3%) were sensitive to augmentin. 21 (30.9%) of the isolates were resistant to vancomycin while 14 (20.6%) were intermediate and 33 (48.5%) were susceptible. The isolates were highly resistant to the macrolides (erythromycin). 63 (92.6%) of the isolates were resistant to erythromycin 5 (7.4%) were intermediate while none was susceptible.

The fluoroquinolones were averagely active against the isolates 24 (35.3%) of the isolates were resistant to ciprofloxain, 7 (10.3%) were intermediate while 37 (54.4) were susceptible 22 (32.4%) of the isolates were resistant to Levofloxacin, 8 (11.8%) were intermediate while 38 (55.8%) were susceptible. 24 (35.3%) of the isolates were resistant to pefloxacin, 10 (14.7%) were intermediate while 34 (50.0%) were susceptible. 28 (41.3%) of the isolates were resistant to ofloxacin, 9 (13.2%) were susceptible. Aminoglycosides (Gentamicin) also exhibited average activity against the isolates. 25 (36.8%) of the isolate were resistant to the gentamicin, 4 (5.8%) were intermediate while 39 (57.4%) were susceptible.

Table 1. Summary of precuring antibiogram of the enterococcal isolates (n=68)

Antibiotics	No (%) of resistant isolates	Prevalence (%) n=632	No (%) of intermediate isolates	No (%) of susceptible isolates
AMP	68 (100)	10.8	-	0 (0)
CL	68 (100)	10.8	0 (0)	0 (0)
AMC	10 (14.7)	1.6	-	58 (85.3)
VAN	21 (30.9)	3.3	14 (20.6)	33 (48.5)
E	63 (92.6)	10.0	5 (7.4)	0 (0)
CIP	24 (35.3)	3.8	7 (10.3)	37 (54.4)
LEV	22 (32.4)	3.5	8 (11.8)	38 (55.8)
PEF	24 (35.3)	3.8	10 (14.7)	34 (50.0)
OFX	28 (41.3)	4.4	9 (13.2)	31 (45.6)
GN	25 (36.8)	4.0	4 (5.8)	39 (57.4)
CXM	49 (72.1)	7.8	12 (17.7)	7 (10.3)
CRO	49(70.)	7.8	19(27.9)	1(1.5)

Key: AMP= Ampicillin. CL= Cloxacillin. AMC= Augmentin. VAN= Vancomycin. E= Erythromycin. CIP= Ciprofloxacin. LEV= Levofloxacin. PEF= Pefloxacin. OFX= Ofloxacin. GN= Gentamicin. CXM= Cefuroxime. CRO= Ceftriaxone

Table 2. Comparison of pre-curing antibiotic resistance profile of the three *Enterococcus* species

Antibiotics	<i>E. faecium</i> N = 39	<i>E. faecalis</i> N = 25	<i>E. avium</i> N = 4	Chi square	p-value
AMP	39 (100)	25 (100)	4 (100)	0	1.000
CL	39 (100)	25 (100)	4 (100)	0	1.000
AMC	6 (15.3)	3 (12.0)	1 (25.0)	5.24	0.07
VAN	16 (41.0)	4 (16.0)	1 (25.0)	11.73	0.002
E	37 (94.9)	23 (92.0)	3 (75.0)	2.51	0.26
CIP	14 (35.9)	8 (32.0)	2 (50.0)	4.56	0.102
LEV	17 (43.6)	5 (20.0)	0 (0)	41.48	0.000
PEF	15 (38.5)	7 (28.0)	2 (50.0)	6.24	0.04
OFX	21 (53.8)	6 (24.0)	1 (25.0)	16.72	0.000
GN	15 (38.5)	7 (28.0)	3 (75.0)	25.81	0.000
CXM	28 (71.7)	20 (80.0)	1 (25.0)	29.85	3.300
CRO	25 (64.1)	22 (88.0)	2 (50.0)	10.96	0.004

Key: Chi square. AMP= Ampicillin. CL= Cloxacillin. AMC= Augmentin. VAN= Vancomycin. E= Erythromycin. CIP= Ciprofloxacin. LEV= Levofloxacin. PEF= Pefloxacin. OFX= Ofloxacin. GN= Gentamicin. CXM= Cefuroxime. CRO= Ceftriaxone

The cephalosporins showed low level of activity against the isolates. 49 (72.5%) of the isolates were resistant to cefuroxime, 12 (17.7%) were intermediate while 7 (10.3%) were susceptible. 48 (70.6%) of the isolates were resistant to ceftriaxone 19 (27.9%) were intermediate while 1 (1.5%) was susceptible.

3.1.2 Antibiotic resistance profile of the three *Enterococcus* species

Penicillins (β -lactams): All the isolates that make up the three species were resistant to the β -lactam antibiotics used for susceptibility testing. They are 100 % resistant to ampicillin

and cloxacillin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi- square statistics and this revealed that there was no significant difference ($p>0.05$) in their resistance to ampicillin and cloxacillin (Table 2).

β -lactam- β - lactamase inhibitor combination (Augmentin): Generally, the resistance of the isolates to augmentin was low. 6 (15.3%) of *E. faecium* were resistant to augmentin; 3 (12.0%) of *E. faecalis* were resistant to augmentin while 1 (25%) of *E. avium* was resistant to augmentin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-

Table 3. Comparison of pre- curing antibiotic resistance of nosocomial isolates and community acquired enterococcal isolates

Antibiotics	Nosocomial isolates n = 41	Community acquired isolates n = 27	CHI-S	P-VAL
AMP	41 (100)	27 (100)	0	1.00
CL	41 (100)	27 (100)	0	1.00
AMC	8 (19.5)	2 (7)	5.53	0.01
VAN	15 (36.6)	6 (22)	3.64	0.05
E	41 (100)	22 (81.5)	1.98	0.17
CIP	16 (39.0)	8 (29.6)	1.28	0.25
LEV	17 (41.5)	5 (18.5)	8.82	0.002
PEF	18 (39.0)	8 (29.0)	1.47	0.22
OFX	20 (48.8)	8 (29.6)	4.70	0.03
GEN	15 (36.6)	10 (37.0)	0.002	0.96
CXM	39 (95.1)	10 (37.0)	2.55	0.04
CRO	33 (80.5)	16 (59.3)	3.22	0.07

Key: Chi-S= CHI-SQUARE. P-VAL= P-VALUE. AMP= Ampicillin. CL= Cloxacillin. AMC= Augmentin. VAN= Vancomycin. E= Erythromycin. CIP= Ciprofloxacin. LEV= Levofloxacin. PEF= Pefloxacin. OFX= Ofloxacin. GN= Gentamicin. CXM= Cefuroxime. CRO= Ceftriaxone

Table 4. Summary of post-curing antibiograms of the isolates

Antibiotics	No (%) of (post-curing) resistant isolates	No(%) of (post-curing) intermediate isolates	No(%) of (postcuring) susceptible isolates
AMP	58(85.3)	-	10(14.7)
CL	46(67.6)	0(0)	22(32.4)
AMC	4(5.9)	-	64(94.1)
VAN	16(23.5)	9(13.2)	43(63.3)
E	28(41.2)	2(2.9)	38(55.9)
CIP	16(23.5)	4(5.9)	48(70.6)
LEV	18(26.5)	2(2.9)	48(70.6)
PEF	20(29.4)	3(4.4)	45(66.2)
OFX	15(22.1)	5(7.4)	48(70.6)
GEN	5(7.4)	1(1.5)	62(91.2)
CXM	42(61.8)	3(4.4)	23(33.8)
CRO	45(66.2)	5(7.4)	18(26.5)

Key: AMP= Ampicillin. CL= Cloxacillin. AMC= Augmentin. VAN= Vancomycin. E= Erythromycin. CIP= Ciprofloxacin. LEV= Levofloxacin. PEF= Pefloxacin. OFX= Ofloxacin. GN= Gentamicin. CXM= Cefuroxime. CRO= Ceftriaxone

square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to augmentin (Table 2).

Glycopeptides (vancomycin): 16 (41.0%) of *E. faecium* were resistant to vancomycin; 4 (16.0%) of *E. faecalis* were resistant to vancomycin while 1 (25%) was vancomycin resistant *Enterococcus* (VRE). The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to vancomycin (Table 2).

Macrolides (erythromycin): Generally, all the isolates were highly resistant to erythromycin 37

(94.9%) of *E. faecium* were resistant to erythromycin; 23 (92.0%) of *E. faecalis* were resistant to erythromycin and 3 (75.0%) of *E. avium* were resistant to erythromycin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to erythromycin (Table 2).

3.1.3 Fluoroquinolones

Ciprofloxacin: 14 (35%) of *E. faecium* were resistant to ciprofloxacin, 8 (32%) of *E. faecalis* were resistant to ciprofloxacin; 2 (50%) of *E. avium* were resistant to ciprofloxacin.

Table 5. Summary of DNA plasmid pre-curing and post-curing analysis of the isolates

Antibiotics	No (%) of (pre-curing) resistant isolates	No (%) of (pre-curing) intermediate isolates.	No (%) of (post-curing) resistant isolates	No (%) of (post-curing) intermediate isolates	No (%) of isolates cured of plasmids
AMP	68(100)	-	58(85.3)	-	10(14.7)
CL	68(100)	0(0)	46(67.6)	0(0)	22(32.4)
AMC	10(14.7)	-	4(5.9)	-	6(8.8)
VAN	21(30.9)	14(20.6)	16(23.5)	9(13.2)	10(14.7)
E	63(92.6)	5(7.4)	28(41.2)	2(2.9)	38(55.9)
CIP	24(35.3)	7(10.3)	16(23.5)	4(5.9)	11(16.2)
LEV	22(32.4)	8(11.8)	18(26.5)	2(2.9)	10(14.7)
PEF	24(35.3)	10(14.7)	20(29.4)	3(4.4)	11(16.2)
OFX	28(41.3)	9(13.2)	15(22.1)	5(7.4)	17(25)
GEN	25(36.8)	4(5.8)	5(7.4)	1(1.5)	23(33.8)
CXM	49(72.1)	12(17.7)	42(61.8)	3(4.4)	16(23.5)
CRO	49(72.1)	19(27.9)	45(66.2)	5(7.4)	18(26.5)

Key: AMP= Ampicillin. CL= Cloxacillin. AMC= Augmentin. VAN= Vancomycin. E= Erythromycin. CIP= Ciprofloxacin. LEV= Levofloxacin. PEF= Pefloxacin. OFX= Ofloxacin. GN= Gentamicin. CXM= Cefuroxime. CRO= Ceftriaxone




Plate 2. DNA plasmid profile of the first 5 of the isolates

Plasmid profiles of five multiple drug resistance *Enterococcus* species analyzed with 0.8% agarose gel electrophoresis. L is 100bp-1kb ladder (molecular marker). Samples PL1, PL3, PL4 and PL5 are positive for plasmid genes with bands greater than 1000bp while sample PL2 is negative for plasmid genes. Keys: PL1 = *Enterococcus faecium*; PL2 = *Enterococcus faecium*; PL3 = *Enterococcus faecium*; PL4 = *Enterococcus faecalis*; PL5 = *Enterococcus avium*

The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to ciprofloxacin (Table 2).

Levofloxacin: 17 (43.6%) of *E. faecium* were resistant to levofloxacin; 5 (20%) of *E. faecalis* to levofloxacin while 0 (0%) (None) of *E. avium* was resistant to Levofloxacin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to levofloxacin (Table 2).

Pefloxacin: 15 (38.5%) of *E. faecium* were resistant to pefloxacin; 7 (28.0%) of *E. faecalis* were resistant to pefloxacin; 2 (50%) of *E. avium* were resistant to Pefloxacin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to pefloxacin (Table 2).

Table 6. Pre-curing and post-curing antibiograms of the plasmid positive enterococcal isolates

ID no	Specie		CIP	PEF	LEV	OFX	CXM	AMC	CRO	CL	AMP	E	VAN	GN	MAR Index
PL 1	<i>E. faecium</i>	Pre	0 ^R	0 ^R	0 ^R	6 ^R	0 ^R	30 ^S	0 ^R	0 ^R	0 ^R	0 ^R	13 ^R	10 ^R	0.9
		Post	22 ^S	26 ^S	30 ^S	25 ^S	0 ^R	31 ^S	0 ^R	0 ^R	0 ^R	0 ^R	0 ^R	25 ^S	10 ^R
PL3	<i>E. faecium</i>	Pre	26 ^S	0 ^R	0 ^R	25 ^S	14 ^R	29 ^S	15 ^I	0 ^R	0 ^R	0 ^R	10 ^R	0 ^R	0.7
		Post	26 ^S	29 ^S	31 ^S	26 ^S	13 ^R	30 ^S	16 ^I	0 ^R	0 ^R	0 ^R	0 ^R	21 ^S	0 ^R
PL 4	<i>E. faecalis</i>	Pre	0 ^R	10 ^R	14 ^R	0 ^R	0 ^R	30 ^S	0 ^R	0 ^R	0 ^R	0 ^R	14 ^R	16 ^S	0.8
		Post	20 ^I	31 ^S	32 ^S	21 ^S	0 ^R	25 ^S	0 ^R	0 ^R	0 ^R	0 ^R	0 ^R	14 ^R	17 ^R
PL5	<i>E. avium</i>	Pre	20 ^I	0 ^R	0 ^R	0 ^R	15 ^I	25 ^S	0 ^R	0 ^R	0 ^R	0 ^R	20 ^S	10 ^R	0.7
		Post	21 ^S	26 ^S	19 ^S	7 ^R	16 ^I	34 ^S	0 ^R	0 ^R	0 ^R	0 ^R	0 ^R	21 ^S	9 ^R
PL 9	<i>E. faecalis</i>	Pre	0 ^R	20 ^S	0 ^R	20 ^S	0 ^R	30 ^S	10 ^R	0 ^R	0 ^R	0 ^R	13 ^R	0 ^S	0.8
		Post	32 ^S	22 ^S	25 ^S	25 ^S	0 ^R	28 ^S	10 ^R	0 ^R	0 ^R	0 ^R	0 ^R	15 ^I	0 ^R
PL 10	<i>E. faecalis</i>	Pre	0 ^R	0 ^R	0 ^R	0 ^R	0 ^R	28 ^S	0 ^R	0 ^R	0 ^R	0 ^R	15 ^I	10 ^R	0.8
		Post	22 ^S	31 ^S	22 ^S	27 ^S	0 ^R	35 ^S	0 ^R	0 ^R	0 ^R	0 ^R	0 ^R	22 ^S	11 ^R
CTL	ATCC 29212		25 ^S	20 ^S	20 ^S	19 ^S	20 ^S	25 ^S	24 ^S	18 ^S	18 ^S	26 ^S	20 ^S	18 ^S	0

Key: S = Sensitise; R = Resistant; I = Intermediate; CTL = Control; MAR = Multiple antibiotic resistance. AMP= Ampicillin. CL= Cloxacillin. AMC= Augmentin. VAN= Vancomycin. E= Erythromycin. CIP= Ciprofloxacin. LEV= Levofloxacin. PEF= Pefloxacin. OFX= Ofloxacin. GN= Gentamicin. CXM= Cefuroxime. CRO= Ceftriaxone

Ofloxacin: 21 (53.8%) of *E. faecium* were resistant to Ofloxacin; 6 (24%) of *E. faecalis* were resistant to ofloxacin; 1 (25%) of *E. avium* were resistant to Ofloxacin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to ofloxacin (Table 2).

Aminoglycosides (Gentamicin) 15 (38.5%) of *E. faecium* were resistant to Gentamicin; 7 (28.0%) of *E. faecalis*; 3 (75%) of *E. avium* were resistant to Gentamicin. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to Gentamicin (Table 2).

3.1.4 Cephalosporins (cephems)

Cefuroxime: 28 (71.7%) of *E. faecium* were resistant to Cefuroxime, 20 (80.0%) of *E. faecalis* were resistant to Cefuroxime 2 (50%) of *E. avium* were resistant to Cefuroxime. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to Cefuroxime (Table 2).

Ceftriaxone: 25 (64.1%) of *E. faecium* were resistant to ceftriaxone; 22 (88.0%) of *E. faecalis* were resistant to ceftriaxone while 2 (50%) of *E. avium* were resistant to ceftriaxone. The pre-curing antibiogram of the three *Enterococcus* species were compared using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to ceftriaxone (Table 2).

3.1.5 Pre-curing antibiotic resistance of nosocomial isolates compared with community acquired isolates

β -lactams: (Ampicillin and cloxacillin): 41 (100%) of the nosocomial isolates were resistant to Ampicillin and Cloxacillin while 27 (100%) of the community acquired isolates were resistant to Ampicillin and Cloxacillin. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to ampicillin and cloxacillin (Table 3).

β -lactam- β -lactamase inhibitor combination (Augmentin): The nosocomial isolates

registered low resistance to Augmentin. Only 8 (19.5%) of the nosocomial isolates were resistant to Augmentin. 2 (7%) of the community acquired isolates were resistant to Augmentin. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to augmentin (Table 3).

Glycopeptides (Vancomycin): 15 (36.6%) of the nosocomial isolates were resistant to vancomycin while 6 (22%) of the community acquired group were resistant to vancomycin. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to vancomycin (Table 3).

Macrolides (Erythromycin): 41 (100%) of the nosocomial isolates were resistant to Erythromycin while 22 (81.5%) of the community acquired isolates were resistant to Erythromycin. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to erythromycin (Table 3).

3.1.6 Fluoroquinolones

Ciprofloxacin: 16 (39.0%) of the nosocomial isolates were resistant to Ciprofloxacin while 8 (29.6%) of the community acquired group were resistant. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p > 0.05$) in their resistance to ciprofloxacin (Table 3).

Levofloxacin: 17 (41.5%) of the nosocomial group were resistant to levofloxacin while 5 (18.5%) of the community acquired isolated were resistant. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was significant difference ($p < 0.05$) in their resistance to levofloxacin (Table 3).

Pefloxacin: 16 (39.0%) of the nosocomial isolates were resistant to pefloxacin while 8 (29.6%) of the acquired isolates were resistant to pefloxacin. The pre-curing antibiogram of

nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p>0.05$) in their resistance to pefloxacin (Table 3).

Ofloxacin: 20 (48.8%) of the nosocomial isolates were resistant to ofloxacin while 8 (29.6%) of the community acquired isolates were resistant to ofloxacin. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was significant difference ($p<0.05$) in their resistance to ofloxacin (Table 3).

Aminoglycosides (Gentamicin): 15 (36.6%) of the nosocomial isolates were resistant to Gentamicin while 10 (37.0%) of the community acquired isolates were resistant to Gentamicin. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p>0.05$) in their resistance to gentamicin (Table 3).

3.1.7 Cephalosporins

Cefuroxime: 39 (95.1%) of nosocomial isolates were resistant to Cefuroxime while 10 (37.0%) of the community acquired group were resistant to Cefuroxime. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was significant difference ($p<0.05$) in their resistance to cefuroxime (Table 3).

Ceftriaxone: 33 (80.5%) of the nosocomial group were resistant to Ceftriaxone while 16 (59.3%) of the community acquired group were resistant to Ceftriaxone. The pre-curing antibiogram of nosocomial isolates was compared with community acquired isolates using Chi-square statistics and this revealed that there was no significant difference ($p>0.05$) in their resistance to ceftriaxone (Table 3).

3.1.8 Summary of post-curing antibiograms of the isolates

Penicillins (β -lactams): 58 (85.3%) of the isolates were resistant to ampicillin after curing of the isolates as shown in Table 4 while 10 (14.7%) were susceptible. 46 (67.6%) of the isolates were resistant to cloxacillin while 22 (32.4%) were susceptible.

β -lactam β -lactamase inhibitor: 4 (5.9%) of the isolates were resistant to Augmentin while 64 (94.1%) were susceptible.

Glycopeptides: 16 (23.5%) of the isolates were resistant to vancomycin 9 (13.2%) intermediate whereas 43 (63.3%) were susceptible

Macrolides: 28 (41.2%) of the isolates were resistant to Erythromycin, 2 (2.9%) intermediate and 38 (55.9%) susceptible.

Fluoroquinolones: 16 (23.5%) of the isolates were resistant to ciprofloxacin 4 (5.9%) were intermediate, whereas 48 (70.6%) of the isolates were susceptible. 20 (29.4%) of the isolates were resistant to pefloxacin 3 (4.4%) intermediate and 45 (66.2%) were susceptible. 15 (22.1%) of the isolates were resistant to pefloxacin, 5 (7.4) were intermediate, 48 (70.6%) were susceptible.

Aminoglycosides: 5 (7.4%) of the isolates were resistant to Gentamicin, 1 (1.5%) was intermediate whereas 62 (91.2%) were susceptible.

Cephalosporins: 42 (61.8%) of the isolates were resistant to cefuroxime, 3 (4.4%) intermediate and 23 (33.8%) susceptible 45 (61.2%) of the isolates were resistant to ceftriaxone, 5 (7.4%) intermediate and 18 (26.5%) susceptible.

3.1.9 Summary of DNA plasmid pre-curing and post curing analysis of the isolates as shown in Table 5

Penicillins (β -lactams) 10 (14.7%) of the Isolate were cured of the plasmid DNA. This meant that 14.7% of ampicillin resistance was plasmid mediated. 22 (32.4%) of the isolates were cured of cloxacillin resistance plasmid DNA.

β -lactam β -lactamase inhibitor: 6 (8.5%) of the isolates were cured of augmentin resistant plasmid DNA

Glycopeptide: 10 (14.7%) of the isolates were cured of vancomycin resistance plasmid DNA.

Macrolides: 38 (55.9%) of the isolates were cured of erythromycin resistance plasmid DNA.

Fluoroquinolones: 11 (16.2%) of the isolates were cured of ciprofloxacin resistant plasmid DNA. 10 (14.7%) of the isolates were cured of levofloxacin resistance plasmid DNA. 11 (16.2%) of the isolates were cured of pefloxacin resistant

plasmid DNA. 17 (25%) of the isolates were cured of ofloxacin resistance plasmid DNA

Aminoglycoside: 23 (33.8%) of the isolates were cured of gentamicin resistance plasmid DNA.

Cephalosporins: 16 (23.5%) of the isolates were cured of cefuroxime resistance plasmid DNA while 18 (26.5%) were cured of ceftriaxone resistance plasmid DNA.

3.1.10 Pre-curing and post-curing antibiograms of the six plasmid positive enterococcal isolates

The pre-curing and post-curing antibiograms of the six plasmid positive isolates were shown on Table 6. The identification numbers are PI1, PI3, PI4, PI5, PI9 and PI10 with CTL as control. These represent *E. faecium*, *E. faecalis*, *E. avium*, *E. faecalis* and *E. faecalis* respectively. The pre-curing multiple antibiotic resistance (MAR) index for the first isolate PI1 (*E. faecium*) was 0.9 while the post-curing MAR index was 0.5. The pre-curing multiple antibiotic (MAR) index for second isolate (*E. faecalis*) was 0.7 while the post-curing MAR index was 0.4. Generally the pre-curing MAR index ranged from 0.7 to 0.9 while the post-curing MAR index ranged from 0.4 to 0.6.

3.1.11 DNA plasmid profile of the representative isolates

Six of the 15 representative isolates selected on the basis of their high pre-curing antibiotic resistance for plasmid analysis with 0.8 agarose electrophoresis were positive for plasmid DNA

(Table 7). Four (4) of the positive isolates (*E. faecium*, *E. faecium*, *E. faecalis*, and *E. avium*) had plasmid fragment of greater than 1000 bp while two (2) of them (*E. faecalis* and *E. faecalis*) had fragments of between 100 and 500 bp. The remaining nine (9) had no plasmid DNA. Plate 2 shows five isolates analysed with 0.8% agarose gel electrophoresis. Samples PL1, PL3, PL4 and PL5 were positive for plasmid genes with bands greater than 1000 bp while sample PL12 was negative.

Plate 3 shows five isolates analysed with 0.8 agarose gel electrophoresis. Samples PL9 and PL10 were positive for plasmid genes with bands between 100 and 500bp while samples PL6, PL7 and PL8 were negative for plasmid genes. Plate 4 shows five isolates analysed with 0.8 % agarose gel electrophoresis. Samples PL11, PL12, PL13, PL19 and PL24 were negative for enterococcal plasmid genes.

Pathogenicity factors: Virulent determinants demonstrated with the enterococcal isolates during the study are displayed on Table 8.

Haemolysin: Of the thirty nine (39) *E. faecium* isolates, twenty six (26) were positive for haemolysin while thirteen (13) were negative. Of the twenty five (25) *E. faecalis* isolates, seventeen (17) were positive for haemolysin while eight (8) were negative. Of the four (4) *E. avium* isolates, one (1) was positive while three (3) were negative. In total, 44 (64.7%) of the isolates were positive for haemolysin while 34 (35.3%) were negative.

Table 7. DNA plasmid profile of the representative enterococcal isolates

Isolate id	Names of isolates	Plasmid fragment
PL1	<i>E. faecium</i>	>1000bp
PL2	<i>E. faecium</i>	Nil
PL3	<i>E. faecium</i>	>1000bp
PL4	<i>E. faecalis</i>	>1000bp
PL5	<i>E. avium</i>	>1000bp
PL6	<i>E. faecium</i>	Nil
PL7	<i>E. faecium</i>	Nil
PL8	<i>E. faecium</i>	Nil
PL9	<i>E. faecalis</i>	Between 100 and 500bp
PL10	<i>E. faecalis</i>	Between 100 and 500bp
PL11	<i>E. faecalis</i>	Nil
PL12	<i>E. faecalis</i>	Nil
PL13	<i>E. avium</i>	Nil
PL19	<i>E. avium</i>	Nil
PL24	<i>E. avium</i>	Nil




Plate 3. DNA plasmid profile of the second 5 of the enterococcal isolates

Plasmid profiles of five multiple drug resistance *Enterococcus* isolates analyzed with 0.8% agarose gel electrophoresis. L is 100bp-1kbp ladder (molecular marker). Samples PL9 and PL10 are positive for plasmid genes with bands greater than 200bp while samples PL6, PL7 and PL8 are negative for plasmid genes. Key: PL6 = *Enterococcus faecium*; PL7 = *Enterococcus faecium*; PL8 = *Enterococcus faecium*; PL9 = *Enterococcus faecalis*; PL10 = *Enterococcus faecalis*



Plate 4. DNA plasmid profiles of 5 of the enterococcal isolates

Plasmid profiles of five multiple drug resistant *Enterococcus* isolates analysed with 0.8% agarose gel electrophoresis. L is 100 bp-1 kbp ladders (molecular marker). Samples PL11, PL12, PL13, PL19 and PL24 were negative for enterococcal plasmid genes. Keys: PL11 = *Enterococcus faecalis*; PL12 = *Enterococcus faecium*; PL13 = *Enterococcus avium*; PL19 = *Enterococcus avium*; PL24 = *Enterococcus avium*

Table 8. Virulent determinants of the enterococcal isolates

Virulent factors		<i>E. faecium</i> (n=39)	<i>E. faecalis</i> (n=25)	<i>E. avium</i> (n=4)	Total (%)
Haemolysin	Positive	26	17	1	44 (64.7)
	Negative	13	8	3	24 (35.3)
Gelatinase	Positive	2	25	0	27 (39.7)
	Negative	37	0	4	41 (60.3)
Caseinase	Positive	25	10	2	37 (54.4)
	Negative	14	15	2	31 (45.6)
Lipase	Positive	20	21	1	42 (61.8)
	Negative	19	4	3	26 (38.2)
MSCRAMM-ACE	Positive	2	1	1	4 (5.9)
	Negative	37		3	64 (94.1)
β -lactamase	Positive	19	14	2	35 (51.5)
	Negative	20	11	2	33 (48.5)

Gelatinase: Of the thirty nine (39) *E. faecium* isolates, two (2) were positive while thirty seven (37) were negative. The twenty five (25) isolates of *E. faecalis* were positive for gelatinase. The four (4) *E. avium* isolates were negative for gelatinase. In total, 27 (39.7%) of the isolates were positive for gelatinase while 41 (60.3%) were negative.

Caseinase: Of the 39 *E. faecium* isolates, 25 were positive for caseinase while 14 were negative. Of the 25 isolates of *E. faecalis*, 10 were positive for caseinase while 15 were negative. Of the 4 *E. avium* isolates, 2 were positive while 2 were negative. In total, 37 (54.4%) of the isolates were positive for caseinase while 31 (45.6%) were negative.

Lipase: Of the 39 *E. faecium* isolates 20 were positive for lipase while 19 were negative. Of the 25 isolates of *E. faecalis*, 21 were positive while 4 were negative. Of the 4 *E. avium* isolates, 1 was positive while 3 were negative. In total, 42 (61.2%) were positive for lipase while 26 (38.8%) were negative.

Microbial surface component recognizing adhesive matrix molecule adhesin of collagen from enterococci MSCRAMM ACE: Of the thirty nine (39) *E. faecium* isolates, two (2) were positive for MSCRAMM ACE while thirty seven (37) were negative. Of the twenty five (25) *E. faecalis* isolates, one (1) was positive while twenty four (24) were negative. Of the four (4) *E. avium* isolates, one (1) was positive for MSCRAMM ACE while three (3) were negative. In total, 4 (5.9%) of the enterococcal isolates were positive for MSCRAMM-ACE while 64 (94.1%) were negative.

β -lactamase production: β -lactamase enzyme was detected in 19 out of the 39 isolates of *E. faecium* while 20 were negative. Of the 25 isolates of *E. faecalis*, 14 were positive for β -lactamase while 11 were negative. Of the 4 isolates of *E. avium* 2 were positive for β -lactamase while 2 were negative. In total, 35 (51.5%) were positive for β -lactamase production while 33 (48.5%) were negative.

4. DISCUSSION

4.1 Prevalence of Vancomycin Resistant Enterococci

The prevalence of vancomycin resistant *Enterococcus* (VRE) in this study was 3.3%

whereas its percentage among the isolates was 30.9%. This is corroborated by the report of Fisher and Philips [2] that in the last three decades, particularly virulent strains of *Enterococcus* that were resistant to vancomycin (vancomycin resistant *Enterococcus* or VRE) have emerged in nosocomial infections of hospitalized patients. The seriousness of this situation will be clearer with the work of Bearman and Winzel, [25] in United Kingdom which demonstrated that the risk of death from vancomycin-resistant enterococci (VRE) is 75%, compared with 45% for those infected with a susceptible strain.

4.2 Antibiotic Susceptibility Patterns of the Isolates

68(100%) of the isolates were resistant to the penicillins (β -lactams) in this work which were ampicillin and cloxacillin. The cephalosporins showed low level of activity against the isolates. 49 (72.5%) of the isolates were resistant to cefuroxime, 12 (17.7%) were intermediate while 7 (10.3%) were susceptible. 48 (70.6%) of the isolates were resistant to ceftriaxone 19 (27.9%) were intermediate while 1 (1.5%) was susceptible. The isolates were highly resistant to the macrolides (erythromycin). 63 (92.6%) of the isolates were resistant to erythromycin 5 (7.4%) were intermediate while none was susceptible. This agreed with the work of David *et al.* [26] who reported resistance to erythromycin to be 73.8% and cloxacillin 84.5%. These findings also agreed with the report of Calva *et al.* [27] who observed the resistance of enterococci to erythromycin. In summary, the pre-curing antibiogram showed that the isolates were completely resistant to ampicillin and cloxacillin (β -lactams), almost completely resistant to erythromycin (aminoglycoside), cefuroxime and ceftriaxone (cephalosporins). This is in accordance with the report of Ryan and Ray [1] which stated that some enterococci are intrinsically resistant to some β -lactam-based antibiotics (some penicillin and virtually all cephalosporins) as well as many aminoglycosides. β -lactam- β -lactamase inhibitor which was represented by augmentin, exhibited a high level of activity on the isolates. 10 (14.7%) of the isolates were resistant to augmentin while 56 (85.3%) were sensitive to augmentin. 21 (30.9%) of the isolates were resistant to vancomycin while 14 (20.6%) were intermediate and 33 (48.5%) were susceptible.

The fluoroquinolones were averagely active against the isolates 24 (35.3%) of the isolates

were resistant to ciprofloxacin, 7 (10.3%) were intermediate while 37 (54.4%) were susceptible. 22 (32.4%) of the isolates were resistant to levofloxacin, 8 (11.8%) were intermediate while 38 (55.8%) were susceptible. 24 (35.3%) of the isolates were resistant to pefloxacin, 10 (14.7%) were intermediate while 34 (50.0%) were susceptible. 28 (41.3%) of the isolates were resistant to ofloxacin, 9 (13.2%) were susceptible. This agreed with the work of David *et al.* [26] who reported that resistance to fluoroquinolones ranged between ofloxacin (33.3%), pefloxacin (36.3%), norfloxacin (31.9%), ciprofloxacin (35.6%), levofloxacin (44.7%) and sparfloxacin (39.3%). Aminoglycosides (Gentamicin) also exhibited average activity against the isolates. 25 (36.8%) of the isolate were resistant to the gentamicin, 4 (5.8%) were intermediate while 39 (57.4%) were susceptible. David *et al.* [26] also reported that out of 568 *E. faecalis* strains isolated and tested for susceptibility 445 (78.3%) showed resistance to tetracycline, 420 (73.9%) to erythromycin, 457 (80.5%) to amoxicillin and 254 (44.7%) to gentamicin and that the highest and the least resistances were observed against cloxacillin and vancomycin with 84.5% and 17.43% respectively. He concluded that isolates were resistant to most antibiotics commonly used in clinical practice. Resistance to most antibiotics is very likely because the genes encoding resistance to these antimicrobials may be located on the same plasmid [28].

Please mention Ref. No. 27 after Ref 26
See Ref 27 highlighted above after 26

4.3 Antibiotic Resistant Profile of the Three *Enterococcus* Species

Penicillins: It is noted that all the three *Enterococcus* species isolated in this study were resistant to the penicillins evaluated. This has probably got to do with the presence of β -lactamase enzyme in the isolates and other resistance mechanisms. β -lactamase enzyme is an enzyme that breaks the β -lactam ring of the Penicillins (β -Lactams), thus rendering them ineffective against the organisms.

β -lactam- β -lactamase inhibitor combination (augmentin). The isolates in this study were found to register low resistance against augmentin. This is a result of the presence of β -lactamase inhibitor which prevents the β -lactamase produced by the isolates to break the β -lactam ring of the antibiotic.

Vancomycin: *E. faecium* was found to be averagely resistant to vancomycin (41%). *E. faecalis* has low resistance (16%) while *E. avium* also has low resistance (25%). The vancomycin resistance of *E. faecalis* (16%) and *E. avium* (25%) was in line with the report of David *et al.* [26] which recorded a low average vancomycin resistance of 17.4%

Erythromycin: the resistance of the isolates to Erythromycin was marked; *E. faecium* (94.9%), *E. faecalis* (92%); *E. avium* (75%). This is in accordance with the report of David *et al.* [26] which recorded 73.9% resistance to erythromycin.

4.4 Fluoroquinolones

Ciprofloxacin: this study showed an average resistance of the isolates to Ciprofloxacin; *E. faecium* (35%); *E. faecalis* (32%); *E. avium* (50%). This is in line with the report of David *et al.* [26] which recorded 35.6% resistance to ciprofloxacin.

Levofloxacin: *E. faecium* had an average resistance of 43.6%; *E. faecalis* had 20% resistance to levofloxacin and isolates of *E. avium* were not resistant to levofloxacin. **Pefloxacin:** *E. faecium* had 38.5% resistance to pefloxacin. *E. faecalis* had 28% resistance to pefloxacin and *E. avium* had 50% resistance to pefloxacin.

Ofloxacin: The resistance of *E. faecium* to ofloxacin was high (53.8%) but *E. faecalis* and *E. avium* registered low resistance 24% and 25% respectively.

Gentamicin: Resistance to gentamicin by *E. faecium* was 38.5%. *E. faecalis* 18% and *E. avium* 75%.

Cephalosporins:

Cefuroxime: *E. faecium* and *E. faecalis* registered high resistance of 71.7% and 80.0% respectively while *E. avium* registered low resistance of 25% to cefuroxime.

Ceftriaxone: The resistance of the three species to Ceftriaxone was high; *E. faecium* (64.0%); *E. faecalis* (88.1%); *E. avium* (50%). This is in line with the report of Oni *et al.* [29].

4.5 Precuring Antibiotic Resistance of Nosocomial Isolates and Community Acquired Isolates

The degree of resistance to some routine antibiotics used in this study by the enterococcal isolates from hospital acquired group was significantly higher than that shown by the community group. Such routine antibiotics include augmentin, levofloxacin, ofloxacin and cefuroxime. Others that showed no significant differences were ampicillin, cloxacillin, vancomycin, erythromycin, ciprofloxacin, pefloxacin, gentamicin and ceftriaxone. However, a high sensitivity of 60% and above was observed in augmentin, vancomycin, ciprofloxacin, levofloxacin, pefloxacin, ofloxacin and gentamicin. The antibiotics sensitivity profile in this study goes a long way to describe the degree of drug abuse and misuse of common routine antibiotics in our society. In addition, continuous exposure of bacteria to routine antibiotics used in the hospital consequently leads to development of resistant strains [29].

4.6 Multiple Antibiotic Resistance (MAR) Index

This is a measure of the response of isolates to an array of antibiotics. This is calculated as the ratio of the number of antibiotics to which the isolate is resistant to the total number of antibiotics to which the isolate is evaluated for susceptibility [30]. The higher the MAR index, the more multiple antibiotic resistant the isolate is.

The pre-curing multiple antibiotic resistance (MAR) index for *E. faecium* was 0.9 while the post-curing MAR index was 0.5. The pre-curing multiple antibiotic (MAR) index for *E. faecalis* was 0.7 while the post-curing MAR index was 0.4. Generally the pre-curing MAR index ranged from 0.7 to 0.9 while the post-curing MAR index ranged from 0.4 to 0.6. The precuring MAR index in this study is outrageous compared with the work of Osundiya *et al.* [30] whose MAR index of *Pseudomonas* and *Klebsiella* was 0.4. This has confirmed the fears that have been expressed as regards the intrinsic resistance and acquisition of resistance factors by bacteria that may result to the emergence of super bugs which may resist all available antibiotics. Of great concern is the ability of vancomycin resistant enterococci to transfer vancomycin resistance to other bacteria (including methicillin resistant *Staphylococcus aureus*) [1].

4.7 Plasmid Detection

DNA plasmids were detected in 40% of the representative isolates with DNA fragments (molecular sizes) ranging from >100bp to 1000bp. This is in line with the report of Marcinek *et al.* [31] that enterococci are known to acquire antibiotic resistance plasmids with relative ease and are able to spread these resistance genes (plasmids) to other species.

4.8 Pathogenicity Factors

Given the importance of *Enterococcus* as a pathogen and increasing prevalence of multiple drug resistant *Enterococcus* as shown by this study, the identification of virulent factors associated with invasiveness and disease severity has become an important subject for research. Five pathogenicity factors (virulent determinants) and β -lactamase were demonstrated with the enterococcal isolates during the study.

Haemolysin: Twenty six (66.7%) of the thirty nine (39) *E. faecium* isolates were positive for haemolysin while thirteen (33.3%) were negative. Seventeen (68%) of the twenty five (25) *E. faecalis* isolates were positive for haemolysin while eight (32%) were negative. One (25%) out of the four (4) *E. avium* isolates was positive while three (75%) were negative. In total, 44 (64.7%) were positive for haemolysin while 24 (35.3%) were negative. Haemolysin is a cytotoxic protein capable of lysing human, horse and rabbit erythrocytes and haemolysin producing strains are found to be associated with increased severity of infection [22].

Gelatinase: Two (5.1%) of the thirty nine (39) *E. faecium* isolates were positive for gelatinase while thirty seven (94.9%) were negative. The twenty five (100%) isolates of *E. faecalis* were positive for gelatinase. The four (100%) *E. avium* isolates were negative for gelatinase. Totally, 27 (39.7%) were positive for gelatinase while 41 (60.3%) were negative. Gelatin producing strains of enterococci have been shown to contribute to the virulence of endocarditis in an animal model [32]. Vergis *et al.* [33] showed that 64% of *E. faecalis* isolates from patients with bacteraemia produced gelatinase. Some enterococcal strains (45-68%) produce gelatinase which is an extracellular zinc containing metalloproteinase [8]. Gelatinase can hydrolyse gelatin, collagen, fibrinogen, casein, haemoglobin and other bioactive peptides [9]. It is also responsible for inflamed pulps and periapical lesions in oral infection [8]. Gelatinase has played an important role in the pathogenicity

of most pathogenic bacteria. The enzyme has been associated with disease progression due to its cytotoxic and tissue destructive potential and inhibitory effects on phagocytes [10]. Gelatinase production and activity are higher in clinical than faecal isolates from healthy volunteers [11].

Caseinase: This is extracellular enzyme that catalyzes the hydrolysis of casein, a protein found in milk. Aside supporting the multiplication of the infecting bacteria, caseinase acts as an effective activator of haemolysin which in turn causes the haemolysis of erythrocytes of infected man and other animals [34].

Twenty five (64.1%) of the thirty nine (39) *E. faecium* isolates were positive for caseinase while fourteen (35.9%) were negative. Ten (40%) of the twenty five 25 isolates of *E. faecalis* were positive for caseinase while 15 (60%) were negative. Two (50%) of the four (4) *E. avium* isolates were positive while two (50%) were negative. Totally, 37 (54.4%) of the isolates were positive for caseinase while 31 (45.6%) were negative.

Lipase: This is an exoenzyme that hydrolyzes the lipid triacylglycerol. The most prominent role of this enzyme is digestion of host extracellular lipids for nutrient acquisition which results in sticking to the host tissue and neighbouring cells [35]. This enhances adhesion by degrading host surface molecules thereby liberating new receptors. Additionally, released free fatty acids (FFA) increases unspecific hydrophobic interactions. The biological role of lipase in infection by many organisms is considered the most important step in bacterial infections [36].

Twenty (51.3%) of the thirty nine (39) *E. faecium* isolates were positive for lipase while 19 (48.7%) were negative. Twenty one (84%) of the twenty five (25) isolates of *E. faecalis* were positive for lipase while 4 (16%) were negative. This agrees with the work of Marcia *et al.* [37] who demonstrated that 71.8% of *E. faecalis* presented lipolytic activity. One (25%) of the four (4) *E. avium* isolates was positive while three (75%) were negative. Totally, 42 (61.2%) were positive for lipase while 26 (38.8%) were negative.

Microbial surface component recognizing adhesive matrix molecule adhesin of collagen from enterococci (MSCRAMM ACE): Ace is a collagen binding MSCRAMM on enterococci and is structurally and functionally related to staphylococcal Cna adhesion [38]. Its presence

among both commensal and pathogenic isolates of *E. faecalis* is apparently expressed during infections in humans [39]. Employing anti Ace antibodies, Ace was detected in 90% of enterococcal endocarditis patients' sera samples suggesting that Ace is expressed in vivo [38].

Two (5.1%) of the thirty nine (39) *E. faecium* isolates were positive for MSCRAMM ACE while thirty seven (94.9%) were negative. One (4%) of the twenty five (25) *E. faecalis* isolates was positive while twenty four (96%) were negative. This is not in consonance with the report of Marcia *et al.* [37] who showed that 40.6% of *E. faecalis* caused agglutination of rabbit erythrocyte. One (25%) of the four (4) *E. avium* isolates was positive for MSCRAMM ACE while three (75%) were negative. In total, 4 (5.9%) of the enterococcal isolates were positive for MSCRAMM-ACE while 64 (94.1%) were negative.

β-lactamase production: β-lactamase (also known as penicillinase) is an enzyme produced by some bacteria which has the ability to break the β-lactam ring of β-lactam antibiotics such as penicillins and cephalosporins, deactivating the molecule's antibacterial property. β-lactamase enzyme was detected in 19 out of the 39 isolates of *E. faecium* while 20 were negative. Of the 25 isolates of *E. faecalis*, 14 were positive for β-lactamase while 11 were negative. Of the 4 isolates of *E. avium* 2 were positive for β-lactamase while 2 were negative. In total β-lactamase was detected in 35 (51.5%) of the isolates. This result is not in line with the finding of Rahangdale *et al.* [40] who reported that strains of enterococci that produce β-lactamase are rare. The implication is that more of the enterococci now produce β-lactamase enzyme which helps them to resist penicillins and cephalosporins.

Development of some mechanisms like inhibition of action of virulence factors and β-lactamase or plasmid curing (removal) may provide an alternate method of therapy in the face of antimicrobial resistance.

5. CONCLUSION

It was observed that the prevalence of *Enterococcus* sp. was high and showed multiple drug resistance. It is therefore, advised that more attention should be given to this organism especially VRE.

Adequate antibiotic policy should be articulated and enforced to forestall the emergence of resistant strains and outbreak of the infection. It is recommended that antibiotic sensitivity be obtained before initiation of most antibiotic treatments. The benefits of antibiotic prophylaxis should be thoroughly weighed against the impending resistance to be encountered in the long run. This policy will not only encourage proper treatment of patients but will discourage the indiscriminate use of antibiotics and prevent further development of resistant strains of the bacteria.

CONSENT

Only patients who gave their written consent were recruited for the study.

ETHICAL APPROVAL

Ethical approval was obtained from ESUT Teaching Hospital, Parklane and University of Nigeria Teaching Hospital, Ituku/Ozalla.

ACKNOWLEDGEMENTS

Our unreserved gratitude goes Prof. A.O. Ekundayo, Dr. A.R Akpe, Prince Ugwu Michael Chukwuemeka and all those who contributed to the success of this research and presentation of this manuscript.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ryan, K. J. and Ray, C. G. (Ed). (2004). Sherris medical microbiology (4thEd.). MC Graw Hill, London. 294-295.
2. Fisher, K. and Philips, C. (2009). 'The ecology, epidemiology and virulence of *Enterococcus*'. *Microbiology*. 155 (6): 1749 – 1757.
3. Murray, B. E. (1990). The life and times of *Enterococcus*. *Clinical Microbiology Review*. 3(1): 46–65.
4. Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Sha, S., Radrik, J. F., Pudd, G. R., Brown, W. J., Cardo, D. and Fridkin, S. K. (2003). Infection with vancomycin resistant *Staphylococcus aureus* containing VanA gene. *New England Journal of Medicine*. 348(14): 1342-1347.
5. Yah, S. C., Yusuf, O. E. and Eghafoa, N. O. (2008). Pattern of antibiotic usage by adult population in the city of Benin, Nigeria. *Scientific Research Essay*. 3(3): 81-85.
6. Santagati, M., Campanile, F. and Stefani, S. (2012). Genomic diversification of enterococci in hosts: the role of the mobilome. *Frontiers Microbiology*. 3(95):1-9.
7. Safdar, N. and Maki, D.G. (2002). The commonality of risk factors for nosocomial colonization and infection with antimicrobial resistant *Staphylococcus aureus*, *Enterococcus*, gram-negative bacilli, *Clostridium difficile*, and *Candida*. *Annals of Internal Medicine*. 136(11):834–844.
8. Roberts, J. C., Singh, K. V., Okhuysen, P. C. and Murray, B. E. (2004). Molecular epidemiology of the *fsr* locus and of gelatinase production among different subsets of *Enterococcus faecalis* isolates. *Journal of Clinical Microbiology*. 42(5): 2317-2320.
9. Araújo, Tatiane Ferreira, & Ferreira, Célia Lúcia de Lucas Fortes. (2013). The genus *Enterococcus* as probiotic: safety concerns. *Brazilian Archives of Biology and Technology*, 56(3): 457-466.
10. Singh, K. V., Narrapareddy, S. R., Nannini, E. C. and Murray, B. E. (2005). *Fsr*-dependent production of protease(s) may explain the lack of attenuation of an *Enterococcus faecalis* *fsr* mutant versus a *gelE-sprE* mutant in induction of endocarditis. *Infection and Immunity*. 73: 4888-4894.
11. Kayaoglu, G. and Ørstavik, D. (2004). Virulence factors of *Enterococcus faecalis*: Relationship to endodontic disease. *Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists*. 15(5): 308-320.
12. Fraimow, H. S., Jungkind, D. L., Lander, D. W., Delso, D. R. and Dean, J. L. (1994). Urinary tract infection with an *Enterococcus faecalis* isolate that requires vancomycin for growth. *Annals of Internal Medicine*. 121(1): 22-26.
13. Kirkpatrick, B. D., Harrington, S. M., Smith, D., Marcellus, D., Miller, C., Dick, J.
 - a. Karanfil, L. and Perl, T. M. (1999). An outbreak of vancomycin-dependent *Enterococcus faecium* in a bone marrow

- transplant unit. *Clinical Infectious Diseases* . 29(5): 1268-1273.
14. Costerton, J. W. (2001). Cystic fibrosis pathogenesis and the role of biofilms in persistent Infection. *Trends in Microbiology*. 9(2): 50–52.
 15. O'Toole, G., Kaplan, H. B. and Kolter, R. (2000). Biofilm formation as microbial development. *Annual Review of Microbiology*. 54:49–79.
 16. Miller, M. B. and Bassler, B. L. (2001). Quorum sensing in bacteria. *Annual Review of Microbiology*. 55:165–199.
 17. Lewis, K. (2001). Riddle of biofilm resistance. *Antimicrobial Agents and Chemotherapy*. 45: 999–1007.
 18. Costerton, J. W., Stewart, P. S. and Greenberg, E. P. (1999). Bacterial biofilms: a common cause of persistent infections. *Science*. 284(5418):1318–1322.
 19. Clinical and Laboratory Standards Institute (CLSI) (2012). Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. M100-S22. Wayne, Pennsylvania, U.S.A. 32(3): 27-184.
 20. Pelinescu, D.R., Sasarman, E., Chifiriuc, M.C., Stoica, I., Nohit, A.M., Avram, I., Serbancea, F. and Dimov, T.V. (2009). Isolation and identification of some *Lactobacillus* and *Enterococcus* strains by a polyphasic taxonomical approach. *Romanian Biotechnological Letters*. 14(2): 4225-4233.
 21. Akortha, E.E. and Filgona, J. (2009). Transfer of gentamicin resistance genes among enterobacteriaceae isolated from the outpatients with urinary tract infections attending 3hospitals in Mubi, Adamawa State. *Scientific Research and Essay*.4 (8):745-752.
 22. Upadhyaya P. M. G., Ravikumar, K. L. and Umapathy B. L. (2009). Review of virulent factors of *Enterococcus*: An emerging nosocomial pathogen. *Indian Journal of Medical Microbiology*. 27 (4): 301-305.
 23. Archimbaud, C., Shankar, N., Forestier, C., Baghdayan, A., Gilmore, M. S., Charbonné, F. and Joly, B. (2002). In vitro adhesive properties and virulent factors of *E. faecalis* strains. *Research Microbiology*. 153(2): 75-80.
 24. Gunn, B. A., Dunkelberg, W. E. Jr. and Creitz, J. R. (1972) Clinical evaluation of 2% LSM medium for primary isolation and identification of coagulase positive staphylococci. *American Journal of Clinical Pathology*. 57(2): 236-240.
 25. Bearman, G. M. and Wenzel, R. P. (2005). Bacteraemias: a leading cause of death. *Archives of Medical Research*. 36(6): 646–659.
 26. David, O. M., Oluduro, A. O., Olawale, A. K., Osuntoyinbo, R. T., Olowe, O. A. and Famurewa, O. (2010). Incidence of multiple antibiotic resistance and plasmid carriage among *Enterococcus faecalis* isolated from the hands of health care workers in selected hospitals in Ekiti, Ondo and Osun States, Nigeria. *International Journal of Academic Research*. 2(1) 43 – 47.
 27. Calva, J. J., Sifuentes-Osornio, J. and Ceron, C. (1996). Antimicrobial resistance in fecal flora: Longitudinal community-based surveillance of children from urban Mexico. *Antimicrobial Agents and Chemotherapy*. 40(7): 1699– 1702.
 28. Philippon, A., Arlet, G. and Jacoby, G. A. (2002). Plasmid-determined AmpC-type β -lactamases *Antimicrobial Agents Chemotherapy*. 46(1): 1-11.
 29. Oni, A. A., Mbah, G. A., Ogukunle, M, O., Shittu, O. B. and Bakare, R. A. (2003). Nosocomial infections: Urinary tract infection in patients with indwelling catheters. *African Journal of Clinical Experimental Microbiology*. 4(1): 63-71
 30. Osundiya, O. O., Oladele, R. O. and Oduyebo, O. O. (2013). Multiple antibiotic resistance (MAR) indeces of *Pseudomonas* and *Klebsiella* species isolates in Lagos University Teaching Hospital. *African Journal of Clinical and Experimental Microbiology*. 14(3): 164-168.
 31. Marcinek H., Wirth, R., Muscholl-Silberhorn, A. and Gauer, M. (1998). *Enterococcus faecalis* gene transfer under natural conditions in municipal sewage water treatment plants. *Applied and Environmental Microbiology*. 64(2): 626-632.
 32. Chow, J. W., Tha,l L. A., Perri, M. B., Vazquez, J. A., Donabedian, S .M., Clewell, D. B. and Zervos, M. J. (1993). Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. *Antimicrobial Agents and Chemotherapy*. 37(11): 2474-2477.
 33. Vergis, E. N., Shankar, N., Chow, J. W., Hayden, M. K., Snyderman, D. R., Zervos, M. J. Linden, P. K., Wagener, M.M. and Muder, R.R. (2003). Association between the presence of enterococcal virulence

- factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to *Enterococcus faecalis*. *Clinical Infectious Diseases*. 35(5): 570-575.
34. Titball, R. W., Bell, A. and Munn, C. B. (1985). Role of caseinase from *Aeromonas salmonicida* in activation of haemolysin. *Infection and Immunity*. 49(3): 7556-759.
 35. Stehr, F., Kretschmar, M., Kroger, C., Hube, B. and Schafer, W. (2003). Molecular lipase as virulent factor. *Journal of Molecular Catalysis: B enzymatic*. 22: 347-355.
 36. Jaeger, K.E., Ransac, S., Dijkstra, B. W., Colson, C., van Heuvel, M. V. and Misset, O. (1994). Bacterial lipases. *FEMS Microbiological Reviews*. 15(1): 29-63.
 37. Marcia, T. F., Patricia, M. S. F., Gleize, V. C., Ana, L. D. and Tomomosa, Y. (2006). Virulent-associated characteristics of *Enterococcus faecalis* strain isolated from clinical sources. *Brazilian Journal of Microbiology*. 37(3): 1678-4405.
 38. Rich, R. L., Kreikemeyer, B., Owens, R.T., Labrenz, S., Narayana, S. V., Weinstock, G.M., Murray, B.E. and Höök, M. (1999). Ace is a collagen binding MSCRAMM from *Enterococcus faecalis*. *Journal of Biological Chemistry*. 274(38): 26939-26945.
 39. Duh, R. W., Sing, K. V., Malathum, K. and Muraay, B. E. (2001). In vitro activity of antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an Ace gene probe from *Enterococcus faecalis* for species identification, *Microbial Drug Resistance*. 7: 39-46.
 40. Rahangdale, V. A., Agrawal, G. and Jalgaonkar, S. V. (2008). Study of antimicrobial resistance in enterococci. *Indian Journal of Medical Microbiology*. 26:285-287.
-